Relay Therapeutics, Inc. (RLAY) stock
RLAYNasdaqBiological Products, (No Diagnostic Substances)Fiscal year ends December 31
$16.47−0.80 (-4.63%)
Close on Nov 17, 2026Market cap $3.61BP/E –Yield –
Relay Therapeutics operating cash flow
Operating cash flow is the cash the business generates from its day-to-day operations.
Relay Therapeutics's operating cash flow for the twelve months ending Jun 30, 2026 was -$212.21M. For fiscal 2025 it was -$235.46M. The highest annual figure on record is -$66.13M in fiscal 2019.
Annual operating cash flow
| Period | Period end | Value | Change |
|---|---|---|---|
| FY2025 | Dec 31, 2025 | -$235.46M | – |
| FY2024 | Dec 31, 2024 | -$249.11M | – |
| FY2023 | Dec 31, 2023 | -$300.32M | – |
| FY2022 | Dec 31, 2022 | -$229.49M | – |
| FY2021 | Dec 31, 2021 | -$74.41M | – |
| FY2020 | Dec 31, 2020 | -$102.49M | – |
| FY2019 | Dec 31, 2019 | -$66.13M | – |
Quarterly operating cash flow
Change is against the same quarter a year earlier.
| Period | Period end | Value | Change |
|---|---|---|---|
| Q2 FY2026 | Jun 30, 2026 | -$54.11M | – |
| Q1 FY2026 | Mar 31, 2026 | -$51.11M | – |
| Q4 FY2025 | Dec 31, 2025 | -$44.87M | – |
| Q3 FY2025 | Sep 30, 2025 | -$62.12M | – |
| Q2 FY2025 | Jun 30, 2025 | -$55.26M | – |
| Q1 FY2025 | Mar 31, 2025 | -$73.21M | – |
| Q4 FY2024 | Dec 31, 2024 | -$57.87M | – |
| Q3 FY2024 | Sep 30, 2024 | -$75.08M | – |
| Q2 FY2024 | Jun 30, 2024 | -$65.83M | – |
| Q1 FY2024 | Mar 31, 2024 | -$50.32M | – |
| Q4 FY2023 | Dec 31, 2023 | -$89.19M | – |
| Q3 FY2023 | Sep 30, 2023 | -$75.40M | – |
| Q2 FY2023 | Jun 30, 2023 | -$68.60M | – |
| Q1 FY2023 | Mar 31, 2023 | -$67.13M | – |
| Q4 FY2022 | Dec 31, 2022 | -$57.08M | – |
| Q3 FY2022 | Sep 30, 2022 | -$66.15M | – |
| Q2 FY2022 | Jun 30, 2022 | -$57.09M | – |
| Q1 FY2022 | Mar 31, 2022 | -$49.17M | -205.4% |
| Q4 FY2021 | Dec 31, 2021 | -$39.71M | – |
| Q3 FY2021 | Sep 30, 2021 | -$53.20M | – |
| Q2 FY2021 | Jun 30, 2021 | -$28.14M | – |
| Q1 FY2021 | Mar 31, 2021 | $46.64M | – |
| Q4 FY2020 | Dec 31, 2020 | -$35.27M | – |
| Q3 FY2020 | Sep 30, 2020 | -$24.04M | – |
| Q2 FY2020 | Jun 30, 2020 | -$20.84M | – |
| Q1 FY2020 | Mar 31, 2020 | -$22.33M | – |
| Q4 FY2019 | Dec 31, 2019 | -$22.76M | – |
| Q3 FY2019 | Sep 30, 2019 | -$17.50M | – |
See a number that looks wrong?